>
Pangaea Oncology SA logo

PANG - Pangaea Oncology SA Share Price

€2 0.0  0.0%

Last Trade - 12/05/21

Sector
Healthcare
Size
Micro Cap
Market Cap £32.2m
Enterprise Value £35.0m
Revenue £3.52m
Position in Universe 507th / 726
Bullish
Bearish
Unlock PANG Revenue
Momentum
Relative Strength (%)
1m -4.92%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.95 2.41 2.62 3.06 3.32 4.10 6.71 7.44 +16.0%
+50.0
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, PangaeaOncology SA revenues increased 24% to EUR4.1M. Net lossdecreased 63% to EUR1.8M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Lower net loss reflectsImpairment of Intangible decrease from EUR2.5M (expense) toEUR0K, Amortization in R&D decrease of 25% to EUR2M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PANG Revenue Unlock PANG Revenue

Net Income

PANG Net Income Unlock PANG Revenue

Normalised EPS

PANG Normalised EPS Unlock PANG Revenue

PE Ratio Range

PANG PE Ratio Range Unlock PANG Revenue

Dividend Yield Range

PANG Dividend Yield Range Unlock PANG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PANG EPS Forecasts Unlock PANG Revenue
Profile Summary

Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since December 29, 2016
No. of Shareholders: n/a
No. of Employees: 55
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Madrid Stock Exchange
Shares in Issue 18,725,113
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PANG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PANG
Upcoming Events for PANG
Frequently Asked Questions for Pangaea Oncology SA
What is the Pangaea Oncology SA share price?

As of 12/05/21, shares in Pangaea Oncology SA are trading at €2, giving the company a market capitalisation of £32.2m. This share price information is delayed by 15 minutes.

How has the Pangaea Oncology SA share price performed this year?

Shares in Pangaea Oncology SA are currently trading at €2 and the price has moved by 17.65% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pangaea Oncology SA price has moved by -8.5% over the past year.

What are the analyst and broker recommendations for Pangaea Oncology SA?

Of the analysts with advisory recommendations for Pangaea Oncology SA, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pangaea Oncology SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Pangaea Oncology SA next release its financial results?

Pangaea Oncology SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Pangaea Oncology SA dividend yield?

Pangaea Oncology SA does not currently pay a dividend.

Does Pangaea Oncology SA pay a dividend?

Pangaea Oncology SA does not currently pay a dividend.

When does Pangaea Oncology SA next pay dividends?

Pangaea Oncology SA does not currently pay a dividend.

How do I buy Pangaea Oncology SA shares?

To buy shares in Pangaea Oncology SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pangaea Oncology SA?

Shares in Pangaea Oncology SA are currently trading at €2, giving the company a market capitalisation of £32.2m.

Where are Pangaea Oncology SA shares listed? Where are Pangaea Oncology SA shares listed?

Here are the trading details for Pangaea Oncology SA:

Country of listing: Spain
Exchange: MCE
Ticker Symbol: PANG
What kind of share is Pangaea Oncology SA?

Based on an overall assessment of its quality, value and momentum, Pangaea Oncology SA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Pangaea Oncology SA share price forecast 2021?

Shares in Pangaea Oncology SA are currently priced at €2. At that level they are trading at 32% discount to the analyst consensus target price of 0.00.

Analysts covering Pangaea Oncology SA currently have a consensus Earnings Per Share (EPS) forecast of 0.04 for the next financial year.

How can I tell whether the Pangaea Oncology SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pangaea Oncology SA. Over the past six months, the relative strength of its shares against the market has been 10.66%. At the current price of €2, shares in Pangaea Oncology SA are trading at 10.36% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pangaea Oncology SA PE Ratio?

We were not able to find PE ratio data for Pangaea Oncology SA.

Who are the key directors of Pangaea Oncology SA?

Pangaea Oncology SA's management team is headed by:

Rafael Lopez Dieguez Gamoneda - IND
Rafael Rosell Costa - CHM
Javier Rivela Rodriguez - CEO
Santiago Ramon y Cajal Agueras - DRC
Luis Barcelona Escartin - DRC
Jose Antonio Maestre Alcacer - DRC
Jesus Tejel Gimenez - IND
Who are the major shareholders of Pangaea Oncology SA?

Here are the top five shareholders of Pangaea Oncology SA based on the size of their shareholding:

Hersol XXI, S.L Corporation
Percentage owned: 14.37% (2.69m shares)
Grupopikolin, S.L. Corporation
Percentage owned: 12.89% (2.41m shares)
Global Portfolio Investments SL Corporation
Percentage owned: 11.44% (2.14m shares)
Vidaro Inversiones SL Corporation
Percentage owned: 10.76% (2.01m shares)
Topgenetics, S.L. Corporation
Percentage owned: 8.06% (1.51m shares)
Similar to PANG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.